SCHEMBL4722492

SCHEMBL4722492

CCCCOc1sn[c]c1-c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.40
CYP1A2 P05177 3/20 0.40
CYP3A4 P08684 3/20 0.40
LTA4H P09960 2/20 0.40
CYP2C9 P11712 3/20 0.38
CYP2C19 P33261 3/20 0.38
CYP19A1 P11511 2/20 0.38
CDC7 O00311 1/20 0.36
PLK4 O00444 1/20 0.36
CHEK1 O14757 1/20 0.36
CHUK O15111 1/20 0.36
PDPK1 O15530 1/20 0.36
DYRK3 O43781 1/20 0.36
ROCK2 O75116 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
PAK4 O96013 1/20 0.36
NTRK1 P04629 1/20 0.36
PRKCG P05129 1/20 0.36
INSR P06213 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724094 0.92 ALDH1A1 (0.34) CYP2D6CYP1A2CYP3A4LTA4HCYP2C19
SCHEMBL4723843 0.86 ALDH1A1 (0.37) LTA4HMAPK1SMN1; SMN2KDM4ENPC1
SCHEMBL4723786 0.78 HTR1B (0.39) CYP2C9ALDH1A1L3MBTL1
SCHEMBL4767317 0.77 ALDH1A1 (0.37) KDRSMN1; SMN2KDM4ENPC1ALDH1A1
SCHEMBL4722490 0.76 LTA4H (0.40) CYP2D6CYP1A2CYP3A4LTA4HCYP2C9
SCHEMBL4724668 0.71 SOAT1 (0.43) CYP2D6CYP1A2CYP3A4LTA4HCYP2C9
SCHEMBL4720944 0.70 CYP2D6 (0.40) CYP2D6CYP1A2CYP3A4LTA4HCYP2C9
SCHEMBL4722708 0.70 LTA4H (0.40) CYP2D6CYP1A2CYP3A4LTA4HCYP2C9
SCHEMBL4719732 0.70 CYP2C9 (0.42) CYP2D6CYP1A2CYP3A4LTA4HCYP2C9
SCHEMBL4765696 0.69 CYP2C9 (0.41) CYP2D6CYP1A2CYP3A4LTA4HCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 CYP2D6 112/4885CYP1A2 427/4885CYP3A4 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.